Levosimendan in Acute Kidney Injury Study (LAKIS)
Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury
Sponsor: Orion Corporation, Orion Pharma
A PHASE2/PHASE3 clinical study on Acute Kidney Injury, this trial is ongoing. The trial is conducted by Orion Corporation, Orion Pharma and has accumulated 6 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2_PHASE3
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Orion Corporation, Orion Pharma
- VieCuri Medical Centre
For direct contact, visit the study record on ClinicalTrials.gov .